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Angiogenesis in glioblastoma: just another moving target? 
 
Inhibition of angiogenesis as a concept has experienced a renaissance in Neuro-
Oncology in 2009. Based on encouraging phase II data suggesting increased 
response rates and improved quality of life including a steroid-sparing effect 
(Friedman et al. 2009, Kreisl et al. 2009), bevacizumab, an antibody to vascular 
endothelial-derived growth factor (VEGF), was approved for the treatment of 
recurrent glioblastoma in the US and, e.g., in Switzerland, although not in the 
European Union (Weller and Stupp 2009). Further, the results of a 2:1:2 randomized 
trial comparing the VEGF receptor antagonist, cediranib (Batchelor et al. 2007), with 
the alkylating agent, lomustine, and the combination of cediranib and lomustine in 
patients with recurrent glioblastoma are awaited for the ASCO meeting June 2010. 
Finally, not only bevacizumab (and probably soon cediranib, too), but also another 
antiangiogenic agent, the integrin antagonist, cilengitide (Stupp et al. 2010), are 
currently evaluated in registration trials for patients with newly diagnosed 
glioblastoma. 
 
Theoretical support for the therapeutic approach of angiogenesis inhibition in 
glioblastoma stems from the idea that the endothelial cell is the only stable, reliable 
element in an increasingly heterogenous, chaotic tumor microenvironment. Genetic 
instability of glioma cells might drive rapid selection processes resulting in the 
generation of multiple diverse resistant tumor cell clones. In contrast, it has 
commonly been assumed that (true) endothelial cells, which are non-neoplastic host 
cells recruited by the growing tumors, would be essentially resistant to the 
development of resistance. Yet, clinical experience has tought us already that such 
views are oversimplified. 
 First, not all vessel formation in gliomas depends on VEGF as illustrated by the 
response rates defined by classical neuroradiological response criteria in the range of 
30-50% (Batchelor et al. 2007, Friedman et al. 2009, Kreisl et al. 2009). While it was 
appropriate to welcome these data as promising, it must not escape our notice that at 
least half of the glioblastomas do quite well in the presence of bevacizumab or 
cediranib, indicating that not all glioblastoma-related angiogenesis is VEGF-related. 
Second, the responses to antiangiogenic agents targeting VEGF are commonly 
transient, suggesting that there are effective escape mechanisms of blood vessel 
formation, contradicting the wishful thinking of endothelial resistance to the 
development of resistance. In fact, numerous other molecules including other VEGF 
family members as well as placental-derived, hepatocyte and fibroblast growth factor 
have been implicated in the primary or acquired resistance to VEGF-antagonistic 
treatments. 
Third, in the current issue of Brain, El Hallani and colleagues (2010) address a 
largely neglected phenotype of maintaining tumor perfusion, the formation of vessel-
like structures by the tumor cells themselves, referred to as vasculogenic mimicry of 
the tubular type. They identified a subset of glioblastomas characterized by “blood 
vessels” that were lined by non-endothelial cells. This interpretation was based on 
the presence of collagen IV, a marker of blood vessel basement membranes, in the 
absence of the expression of CD34, a universal marker for endothelial cells. To 
support the idea that the vessel-lining cells were tumor cells, the authors 
demonstrated the amplification of epidermal growth factor receptor in these cells in a 
tumor known to harbour this molecular phenotype. Some of the tumor cells 
expressed smooth muscle actin, indicating that these tumor cells had 
transdifferentiated into vascular smooth muscle-like cells. Intriguingly, the authors 
provide one example of a tissue section where there appears to be an anastomosis 
between an endothelially lined vessel and a tumor-derived “vessel”. Finally, the 
authors analysed the subpopulation of glioma-initiating cells by CD133 sorting from 
two tumors, one with and one without putative tumor-derived blood vessels. CD133+ 
cells from the former tumor generated vessel-like structures in tube formation assays 
whereas the latter did not. An expression of endothelium-associated genes was 
observed in both populations of glioma-initiating cells. These observations led the 
authors to propose that the subpopulation of glioma-initiating cells may even possess 
the plasticity to form blood vessels. Taken together, this study indicates that some 
glioblastomas may grow in the absence of endothelial cell recruitment, suggesting 
that they may exhibit primary refractoriness to therapeutic approaches targeting, e.g., 
VEGF. Admittedly, further studies need to clarify the overall frequency of this 
phenotype and its contribution to the perfusion of glioblastomas in a larger sample of 
tumors. 
 
The introduction of novel antiangiogenic agents has already imposed some new 
challenges on clinical neuro-oncologists, some of which have been faced and almost 
solved whereas others require new approaches. Thus, the response criteria devised 
by Macdonald and colleagues (1990) had to be modified to rely less on contrast 
enhancement, to include the necessity for a confirmation of a response as well as to 
consider tumor extensions on T2-weighted magnetic responance imaging (Van den 
Bent et al. 2009). The latter became necessary when it was recognized that some 
patients treated with bevacizumab exhibited an altered patterns of recurrence 
reminiscent of gliomatosis cerebri which was attributed to a change from vessel- and 
VEGF-dependent growth to a vessel- and VEGF-independent growth (Norden et al. 
2008). Future clinical trials will aim at identifying prospectively biomarkers associated 
with response or lack of response to antiangiogenic agents and such analyses 
should start with a careful neuropathological and neuroradiological characterization 
of the pretreatment vascularisation of these tumors. 
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